ALDEYRA THERAPEUTICS INCALDEYRA THERAPEUTICS INCALDEYRA THERAPEUTICS INC

ALDEYRA THERAPEUTICS INC

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.10EUR
Revenue estimate
‪1.11 M‬EUR
Market capitalization
‪219.50 M‬EUR
−0.58EUR
‪−34.01 M‬EUR
‪57.03 M‬
Beta (1Y)
4.77

About Aldeyra Therapeutics, Inc.

CEO
Todd C. Brady
Headquarters
Lexington
Employees (FY)
10
Founded
2004
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 137 is 3.73 EUR — it has decreased by 2.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ALDEYRA THERAPEUTICS INC stocks are traded under the ticker 137.
ALDEYRA THERAPEUTICS INC is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
137 stock is 2.88% volatile and has beta coefficient of 4.77. Check out the list of the most volatile stocks — is ALDEYRA THERAPEUTICS INC there?
137 earnings for the last quarter are −0.13 EUR per share, whereas the estimation was −0.19 EUR resulting in a 28.49% surprise. The estimated earnings for the next quarter are −0.10 EUR per share. See more details about ALDEYRA THERAPEUTICS INC earnings.
Yes, you can track ALDEYRA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
137 stock has risen by 0.54% compared to the previous week, the month change is a 30.93% rise, over the last year ALDEYRA THERAPEUTICS INC has showed a 55.23% decrease.
137 net income for the last quarter is ‪−4.31 M‬ EUR, while the quarter before that showed ‪−7.74 M‬ EUR of net income which accounts for 44.40% change. Track more ALDEYRA THERAPEUTICS INC financial stats to get the full picture.
Today ALDEYRA THERAPEUTICS INC has the market capitalization of ‪219.50 M‬, it has increased by 1.24% over the last week.
No, 137 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 137 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALDEYRA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
137 reached its all-time high on Sep 26, 2018 with the price of 14.15 EUR, and its all-time low was 1.32 EUR and was reached on Oct 16, 2023.
See other stocks reaching their highest and lowest prices.
As of May 1, 2024, the company has 10.00 employees. See our rating of the largest employees — is ALDEYRA THERAPEUTICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALDEYRA THERAPEUTICS INC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALDEYRA THERAPEUTICS INC stock shows the sell signal. See more of ALDEYRA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ALDEYRA THERAPEUTICS INC future price: according to them, 137 price has a max estimate of 10.16 EUR and a min estimate of 6.46 EUR. Read a more detailed ALDEYRA THERAPEUTICS INC forecast: see what analysts think of ALDEYRA THERAPEUTICS INC and suggest that you do with its stocks.